Not sure what you're talking about here Cato when you refer to "next 22 years". Wombat has used a PE based on pharma industry averages.
The problem with any average is that it can be a pretty blunt instrument. If you look at the PE of some of the high growth businesses (look at the early biotechs like Biogen, Gilead, Regeneron and our own CSL) they have always had much high PEs especially in their early high growth phase.
Wombat's PE looks very conservative to me.
Not sure what you're talking about here Cato when you refer to...
-
- There are more pages in this discussion • 479 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |